Protein-Related Technologies are deployed specifically for research and development of therapeutic proteins. Therapeutic proteins – signalling substances, enzymes and monoclonal antibodies – form by far the most important group of biotechnological agents in current use. Roche research has played a pivotal role in the use of protein-based therapeutics since the introduction of Roferon-A in 1986. These drugs usually display excellent affinity and selectivity for the disease target, favorable molecular properties and a low incidence of side effects. Roche owns and develops cutting edge protein-engineering technologies as well as world-class manufacturing processes and facilities. At Roche, we are actively working on the next wave of therapeutic proteins focusing on rational design, antibody engineering and new therapeutic modalities. In terms of sales, innovation potential and production capacity, Roche is the world’s largest biotech company.
Technologies in this area
A conversation with Roland Beckmann, inventor of the DutaMab technology
Interview with Dutalys co-founder and inventor of the DutaMab technology platform, Roland Beckmann, on his invention and journey founding a biotech.
Antibody Fusion Proteins
Antibody Fusion Proteins are constructs that combine an antibody targeted to a specific antigen, typically a tumor-related antigen, with a protein that is able to amplify the immune response or induce direct damage to the cancer cell.
Antibody-Drug Conjugates (ADCs) are a new class of highly potent biological drugs built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody, with either a permanent or a labile linker.
Asia Partnering at Roche
Our Pharma Partnering team based in China and Japan is actively looking for new partnerships with companies based in Asia.
Bispecific Antibodies combine two or more antigen-recognizing element into a single construct, able to bind to two or more targets.
Brain Shuttle is a technology that we have developed at Roche to increase penetration into the brain of large molecules such as antibodies.
CrossMAbs are better accepted by the body 's immune system and have a reduced risk of immunogenic response compared to traditional bispecific antibodies.
Engineered for treatment success: Cytokine Fusion Proteins
Cytokine fusion proteins stimulate the immune system with high specificity and tolerability and could be a transformative approach to cancer treatment.
Glycoengineering approaches generate new antibody variants with significantly enhanced capacity to recruit immune cells, like Natural Killer (NK) cells.
Locked Nucleic Acid (LNA) Platform
Enabling scientists to develop a new class of medicines against diseases that are difficult, or impossible, to target with antibodies and small molecules.
Monoclonal Antibodies (MAbs) are antibodies that are made by identical immune cells, cloned from a single parent cell.
Organoids: turning science fiction to reality
The Roche Institute for Translational Bioengineering (ITB) is accelerating research into using organoids to predict the safety and efficacy of new molecules.
Tiny labs made of plastic simulate the human body- the Organs-on-a-Chip technology shows new approaches to obtain human-relevant information on a potential drug.
Protein Production requires the gene for the desired human protein to be inserted into an appropriate host cell.
Ten remarkable facts about making antibody medicines
Antibodies are an important part of our immune system and antibody medicines can help fight diseases. Learn about the complex process needed to make them.